1. Home
  2. SKIL vs MDXH Comparison

SKIL vs MDXH Comparison

Compare SKIL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$6.25

Market Cap

40.2M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.56

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIL
MDXH
Founded
1998
2003
Country
United States
Belgium
Employees
2247
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
41.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SKIL
MDXH
Price
$6.25
$0.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
55.6K
1.3M
Earning Date
04-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.11
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$0.51
52 Week High
$18.45
$5.33

Technical Indicators

Market Signals
Indicator
SKIL
MDXH
Relative Strength Index (RSI) 38.82 14.37
Support Level $3.63 $0.51
Resistance Level $8.48 $3.78
Average True Range (ATR) 0.64 0.08
MACD -0.16 0.02
Stochastic Oscillator 12.04 15.49

Price Performance

Historical Comparison
SKIL
MDXH

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: